The pharma industry and the UPC

The UPC and its role in the global patent litigation ecosystem: a look ahead to 2026

At this joint event hosted by Pinsent Masons and JUVE Patent, a group of industry leaders debated how the evolution of the UPC throughout 2025, and ke ...

1 December 2025 by Pinsent Masons LLP

Cases

Gilead, remdesivir, Academy of Military Medical Sciences, Chinese research institute, Hoyng ROKH Monegier

Pharmaceuticals

Gilead attacks remdesivir patent of Chinese research institute at UPC

US biotech company Gilead has filed a new revocation action with the UPC targeting a patent owned by the Chinese Academy of Military Medical Sciences. ...

19 August 2025 by Mathieu Klos

Cases

Boehringer Ingelheim, Zentiva, Ofev, nintedanib, Portugal

Respiratory drug

Court of Appeal grants final victory to Boehringer in PI case against Zentiva

After losing its PI bid at the UPC local division Lisbon in May, Boehringer Ingelheim has now come out on top. The Court of Appeal finds Zentiva is at ...

14 August 2025 by Laura King

Cases

mRNA, covid-19 vaccines, GSK, Moderna, Pfizer, BioNTech, CureVac

mRNA technology

mRNA patent wars kick into higher gear during dog days of summer

The global patent disputes between mRNA vaccine manufacturers have once again set the patent community buzzing. While GSK launched several lawsuits at ...

11 August 2025 by Mathieu Klos